Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + camrelizumab + TACE for liver metastases from GEP-NET
ChiCTR2100050854Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, camrelizumab and irinotecan in Gastroenteropancreatic Carcinoid Tumor and hepatic metastasis, sponsored by Tongji Hospital. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
Rivoceranibcamrelizumabirinotecan
03
Conditions
Gastroenteropancreatic Carcinoid Tumorhepatic metastasis
Beyond the preview
Go deeper on ChiCTR2100050854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050854.